医学
结直肠癌
转移
胃肠病学
内科学
临床终点
化疗
随机对照试验
肝动脉灌注
不利影响
外科
肿瘤科
泌尿科
癌症
作者
Mitsuo Kusano,Michitaka Honda,Koji Okabayashi,Koho Akimaru,Syuichi Kino,Y Tsuji,Masashi Watanabe,Satoshi Suzuki,Takaki Yoshikawa,Junichi Sakamoto,Koji Oba,Shigetoyo Saji
标识
DOI:10.4103/0973-1482.184524
摘要
The feasibility and efficacy of adjuvant hepatic arterial infusion (HAI) in preventing the development of liver metastases in patients with advanced colon carcinoma have not been validated. The aim of this randomized controlled study was to compare the feasibility of HAI and the protective effect against liver metastasis after curative resection to those of systemic chemotherapy.Between July 2000 and June 2003, 91 patients were enrolled. Patients were randomly assigned to receive 5-fluorouracil (5-FU) via continuous venous infusion (CVI) or intra-hepatic arterial weekly high-dose 5-FU (WHF). The primary endpoint was overall survival (OS).In the WHF group, the cumulative failure rate of hepatic arterial catheterization was 16.7% at 6 months. The occurrence of grade 3 adverse events was comparable between the groups. The 5-year OS rates were 59.0% in the CVI group and 34.9% in the WHF group (P = 0.164). CVI tended to show a protective effect against liver metastasis regarding the 5-year liver-specific cumulative recurrence rate: CVI, 45.0% vs. WHF, 68.3%; P = 0.037).HAI therapy has a certain protective effect against liver metastasis after curative resection in patients with colorectal cancer. However, this therapy did not contribute to any marked improvement in their overall survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI